What is Coloplast A/S (CLPBY)?

Coloplast A/S (CLPBY) is a stock in the Healthcare sector, Medical - Instruments & Supplies industry. View full analysis on Stocks360.

What is the current price of CLPBY?

The current price of CLPBY is $7.24. Prices are updated in real time on Stocks360.

What is CLPBY's price-to-earnings (PE) ratio?

CLPBY's trailing twelve-month PE ratio is 39.34, based on current price and earnings per share data available on Stocks360.

What is CLPBY's market capitalization?

CLPBY's market capitalization is $16,316,652,981.00, placing it in the large-cap tier.

Does CLPBY pay a dividend?

Yes. CLPBY has a trailing twelve-month dividend yield of 0.05%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Coloplast A/S (CLPBY)

Stock analysis · OTC · Healthcare · Medical - Instruments & Supplies

$7.24

Market Cap

$16.32B

PE (TTM)

39.34

EPS (TTM)

N/A

Dividend Yield

4.77%

Beta

0.53

Day Range

$7.24 – $7.32

52-wk Range

$5.64 – $9.70

Avg Volume

N/A

Volume

6.28K

Coloplast A/S (CLPBY) is a publicly traded company in the Healthcare sector. Latest price: $7.24. Market cap $16.32B. Trailing PE 39.34. Dividend yield 4.77%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $9.07 2026-10-30 · $7.24 (-20.18%)

Earnings

Most Recent

Aug 18, 2026

EPS $0.10 vs est. $0.10

Beat by $0.00

Next Earnings

Nov 3, 2026

EPS estimate $0.09

Proprietary Signals

Signal snapshot temporarily unavailable.

About Coloplast A/S

Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Its extensive reach spans Denmark, the United States, the United Kingdom, France, and numerous other international regions. The company's activities are organized into three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care. Within Chronic Care, Coloplast provides advanced ostomy solutions, including the SenSura Mio, recognized for its adaptable fit and discretion, alongside other SenSura offerings and Brava brand accessories. This segment also delivers continence care products such as Conveen Active urine bags, SpeediCath catheters for diverse users, and the Peristeen transanal irrigation system. The Wound & Skin Care division features innovative dressings like the conforming Biatain Silicone and the hydrocolloid Comfeel. Additionally, it offers a broad spectrum of skin care items, encompassing bathing and cleansing products, moisturizers, skin protectants, antifungal treatments, hand cleansers, odor control solutions, and the specialized InterDry system for managing skin folds. Finally, the In…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	39.34×
P/S (TTM)	3.82×
P/B	8.13×
P/FCF (TTM)	17.34×
EV / EBITDA	11.12×
EV / Sales	4.63×
Earnings Yield	2.54%
Free Cash Flow Yield	5.77%
Dividend Yield	4.77%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$131.68B
Revenue (TTM)	$28.44B
Net Income (TTM)	$2.76B
Free Cash Flow (TTM)	$6.61B
Net Debt	$22.99B
Working Capital	$3.74B
Gross Margin	58.50%
Operating Margin	26.35%
Net Margin	9.71%
Return on Equity	19.69%
Return on Invested Capital	12.07%